GSK plc

Equities

GSK

GB00BN7SWP63

Pharmaceuticals

Real-time Estimate Cboe Europe 08:57:31 2024-06-10 am EDT 5-day change 1st Jan Change
1,620 GBX -0.55% Intraday chart for GSK plc +1.42% +11.76%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
GSK Says FDA Approved RSV Vaccine's Expanded Age Indication MT
Moderna COVID/flu combo vaccine superior to separate shots in trial RE
Investors remain cautious as political instability takes over Europe Our Logo
GSK gets FDA approval for Arexvy vax in 50-59 year olds at risk of RSV AN
GSK: FDA approves vaccine against respiratory virus CF
UK Stocks-Factors to watch on June 10 RE
FTSE called down amid political uncertainty in EU AN
Indonesia ramps up fight against tuberculosis amid concerns on economic impact RE
GSK : Goldman Sachs reaffirms its Neutral rating ZD
Gsk PLC - FDA Approves Arexvy For Adults 50-59 At Risk RE
GSK Secures Expanded US FDA Approval for RSV Vaccine MT
US FDA expands GSK's RSV vaccine approval to adults aged 50 to 59 RE
GSK says FDA Approves Expanded Age Indication For Arexvy, RSV Vaccine For Adults Aged 50-59 At Increased Risk RE
GSK -CLINICAL DEVELOPMENT PROGRAMME CONTINUES TO EVALUATE SAFETY… RE
GSK - FDA APPROVES EXPANDED AGE INDICATION FOR GSK'S AREXVY, FIR… RE
GSK Vaccine to Prevent Respiratory-Tract Disease Approved for Expanded Use DJ
GSK : JP Morgan maintains a Sell rating ZD
GSK Closes Up to $50 Million Purchase of US-based Elsie Biotechnologies MT
GSK: acquisition of US biotech Elsie CF
GSK Buys Elsie Biotechnologies for Up to $50 Million DJ
GSK Buys Elsie Biotechnologies for $50 Million MT
GSK plc acquired Elsie Biotechnologies for $50 million. CI
HSBC Lifts GSK PT, Maintains Reduce Rating MT
Berenberg raises Taylor Wimpey to 'buy' AN
GSK : DZ Bank remains Neutral ZD
Chart GSK plc
More charts
GSK plc is a global biopharma company. The Company’s segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. Its product areas include vaccines, specialty medicines, and general medicine. It is also focused on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions. Its vaccine portfolio includes over 20 vaccines that help to protect people from a range of diseases and infections, including meningitis, shingles and flu, among others. Its specialty medicines are also engaged in developing medicines for respiratory disease and HIV. Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease, antibiotics, and medicines for skin diseases. It is advancing oligonucleotide therapeutics in chronic hepatitis B and steatotic liver disease as well as other therapeutic areas beyond liver disease.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
16.29 GBP
Average target price
20.36 GBP
Spread / Average Target
+25.01%
Consensus
  1. Stock Market
  2. Equities
  3. GSK Stock
  4. News GSK plc
  5. GSK Plans to Sell About 385 Million Haleon Shares, Bloomberg Reports